Refametinib Uses, Dosage, Side Effects and more

Trade Name Refametinib
Generic Refametinib
Refametinib Other Names Refametinib
Type
Formula C19H20F3IN2O5S
Weight Average: 572.337
Monoisotopic: 572.008970485
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in cancer/tumors (unspecified).

How Refametinib works

RDEA119 is a potent, non-ATP competitive, highly selective inhibitor of MEK. RDEA119 is a highly potent and selective inhibitor of mitogen-activated ERK kinase (MEK), a key component of the RAS/RAF/MEK/ERK pathway that is commonly defective in human tumors. The MEK1/2 pathway is important in cell cycle regulation in inflammatory bowel disease, including ulcerative colitis and Crohn's disease. RDEA119 was shown to reduce damage to colonic tissue in two different mouse models of colitis, murine trinitrobenzene sulfonic acid (TNBS) colitis model and murine dextran sulfate sodium (DSS) colitis model. [Ardea Biosciences Inc. Press release]

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share